Wegovy HD 7.2 mg: what does the higher dose mean?
The higher weekly semaglutide dose approved in the US in 2026: who it is for on the label, how it is reached, trial results, side effects and the maker’s price.
Written for the United States. Other country versions are coming.
Wegovy HD is a 7.2 mg weekly dose of semaglutide, FDA-approved in March 2026 for adult weight management after at least 4 weeks on 2.4 mg. In a 72-week trial, weight fell 18.8% on 7.2 mg, 15.5% on 2.4 mg and 3.9% on a dummy. Nausea and skin tingling were more common.
Key takeaways
- Wegovy HD is a 7.2 mg weekly semaglutide pen the FDA approved on March 19, 2026, for weight management in adults.1
- The US label allows 7.2 mg only after at least 4 weeks on 2.4 mg, when more weight loss is clinically indicated.2
- In STEP UP, weight fell 18.8% on 7.2 mg, 15.5% on 2.4 mg and 3.9% on a dummy injection over 72 weeks; Novo Nordisk paid for it.2,3
- Dysesthesia, a tingling or burning skin feeling, affected 22 in 100 on 7.2 mg against 6 in 100 on 2.4 mg, the US label says.2
- Novo Nordisk lists a self-pay price of $399 a month for Wegovy HD, against $349 for lower pen doses, checked October 12, 2026.4
On this page
What is Wegovy HD, and who is it approved for?
Wegovy HD is a 7.2 mg weekly dose of semaglutide, three times the usual 2.4 mg top dose. The FDA approved it on March 19, 2026, for weight management in adults.1,2
- GLP‑1 medicines are prescription-only in the US. A licensed prescriber decides whether one fits you.
- Label facts here come from the current US Wegovy prescribing information (the “label”), revised June 2026.2
- The label makes 7.2 mg an option after at least 4 weeks on 2.4 mg, “if additional weight reduction is clinically indicated”. It is not a standard next step for everyone.2
- This post describes the label and trials. It is not a plan for your treatment, and no dose guarantees any result. Every risk is in our side-effects guide.
Semaglutide is the medicine; Wegovy is the brand, made by Novo Nordisk. It copies a gut hormone, GLP‑1, that helps regulate appetite and slows how fast your stomach empties.2 “HD” is the name on the 7.2 mg pen.2
- Who the FDA approved it for: adults “with obesity, or overweight with at least one weight-related condition”.1
- Who was in the trials: only adults with a BMI of 30 or more. People with a BMI of 27 to 29.9 were not studied at this dose.2
- Not for: children. The label says the safety of 7.2 mg has not been established in children or in people with MASH (fatty liver disease).2
- Heart-risk use: the label’s maintenance dose for lowering heart risk is 2.4 mg, or 1.7 mg, not 7.2 mg.2
The FDA decided in 54 days after filing, under a fast-track voucher program for national priorities.1
How is the 7.2 mg dose taken?
As one injection a week from a single-dose 7.2 mg pen. You reach it only after the usual step-up to 2.4 mg and at least 4 weeks there.2
| Weeks | Weekly dose | Note |
|---|---|---|
| 1 to 4 | 0.25 mg | Starting dose2 |
| 5 to 8 | 0.5 mg | Step up2 |
| 9 to 12 | 1 mg | Step up2 |
| 13 to 16 | 1.7 mg | Step up2 |
| 17 onward | 1.7 or 2.4 mg | Usual maintenance2 |
| After at least 4 weeks on 2.4 mg | Up to 7.2 mg | Only if more weight loss is clinically indicated2 |
- If a step is hard to tolerate, the label says to consider delaying it for 4 weeks.2
- If one dose is missed and the next is more than 2 days away, take it as soon as possible; if less than 2 days, skip it.2
- If 2 or more doses in a row are missed, the label says to restart the step-up at a lower dose.2
- Keep the pen in the fridge at 36–46°F (2–8°C). Before the cap comes off it can be kept at 46–86°F (8–30°C) for up to 28 days.2
How much more weight did people lose on 7.2 mg?
In STEP UP, weight fell 18.8% on 7.2 mg over 72 weeks, against 15.5% on 2.4 mg and 3.9% on a dummy injection. That is about 3 points more than 2.4 mg.2
How these trials work:
- People are split at random into groups. One group gets a dummy injection (placebo) with no medicine in it.
- Everyone gets the same diet and activity advice.
- The gap between groups is what the medicine added. An average is not a promise: some people lose much more, some very little.
1,407 adults with a BMI of 30 or more and no diabetes, average weight 249 lb (113 kg), for 72 weeks. 86% were White and 4% Asian. Novo Nordisk paid for the trial.2,3
Weight lost, % of starting weight
7.2 mg added about 3.3 points on top of 2.4 mg.2
512 adults with obesity and type 2 diabetes, for 72 weeks.2
Weight lost, % of starting weight
Put another way. In STEP UP, 46 in 100 on 7.2 mg lost at least a fifth of their weight, against 32 in 100 on 2.4 mg and 3 in 100 on the dummy. About 89 in 100 on 7.2 mg lost at least 5%, but so did 38 in 100 on the dummy.2
A worked example. For someone starting at 249 lb (113 kg), 18.8% is about 47 lb (21 kg) and 15.5% about 39 lb (18 kg), by our arithmetic. The extra from the higher dose is about 8 lb (4 kg).
The groups were uneven: 1,005 people got 7.2 mg but only 201 got 2.4 mg.2 Novo Nordisk paid for STEP UP.3
Which side effects are more common at 7.2 mg?
Stomach effects, and an odd skin feeling called dysesthesia. About 22 in 100 people on 7.2 mg reported dysesthesia, against 6 in 100 on 2.4 mg and almost none on the dummy.2
| Side effect | 7.2 mg | 2.4 mg | Dummy |
|---|---|---|---|
| Feeling sick (nausea) | 39 in 100 | 35 in 100 | 13 in 100 |
| Vomiting | 22 in 100 | 16 in 100 | 6 in 100 |
| Altered skin feeling (dysesthesia) | 22 in 100 | 6 in 100 | 0 in 100 |
| Constipation | 20 in 100 | 19 in 100 | 8 in 100 |
| Hair loss | 6 in 100 | 3 in 100 | 1 in 100 |
US Wegovy label, Table 4: adults with obesity in Studies 8 and 9, checked October 12, 2026.2
Dysesthesia means altered skin feeling: tingling, burning, skin pain or skin that is sensitive to touch.2 Among people who had it on 7.2 mg, 18% had not recovered by the end of the trial. Of 38 who went back up to 7.2 mg after it settled, 17 got it again.2
Side effects made 5 in 100 stop on 7.2 mg, the same as on 2.4 mg, against 2 in 100 on the dummy. Stomach problems were the most common reason.2
Builds a printable list for your appointment. No sign-up.
What does Wegovy HD cost, and will insurance pay?
Novo Nordisk’s self-pay price for Wegovy HD is $399 a month, against $349 for the lower pen doses, checked October 12, 2026. Insurance coverage depends on your plan.4
A “month” is one box of 4 pens.4 Novo Nordisk gives the HD pen the same list price as the other Wegovy pens and the pill: $1,349.02 a package.4 TrumpRx, a government price-listing site, shows $1,349 a month for Wegovy.5 A list price is set before discounts and rebates; most insured people pay less.4
For Medicare, CMS’s GLP‑1 Bridge sheet lists “Wegovy (injection and tablets)” for weight. It does not name doses, so we can’t say how it treats the HD pen.6
When is 7.2 mg not used?
The label limits it to adults using Wegovy for weight, after 2.4 mg. Other limits come from the label’s warnings.2
- Children and teens. Safety of 7.2 mg has not been established in anyone under 18.2
- Heart-risk or MASH use. The label’s doses for those uses top out at 2.4 mg.2
- Bad stomach symptoms on 2.4 mg. The label says to consider delaying a step if a dose is not tolerated.2
- Pregnancy. The label says to stop Wegovy at least 2 months before a planned pregnancy because it stays in the body a long time.2
- Medullary thyroid cancer or MEN 2 in you or your family: Wegovy is not used.2
- Pancreatitis (inflammation of the pancreas) has been seen with GLP‑1 medicines. The label says to stop if it is suspected.2
- Gallbladder problems, including gallstones, are a label warning.2
- Kidney injury can follow dehydration from vomiting or diarrhea.2
- Faster resting heart rate is a label warning; the label says to check it regularly.2
- Thyroid tumors were seen in rodents; Wegovy carries a boxed warning.2
Questions people ask
Is Wegovy HD available in the US?
Yes. The FDA approved the 7.2 mg dose, sold as Wegovy HD in a single-dose pen, on March 19, 2026.1,2
How much more weight do you lose on Wegovy 7.2 mg?
In STEP UP, about 3.3 percentage points more than on 2.4 mg over 72 weeks: 18.8% against 15.5%. On a dummy injection it was 3.9%.2
Can you start Wegovy at 7.2 mg?
No. The label starts at 0.25 mg and steps up every 4 weeks. 7.2 mg comes only after at least 4 weeks on 2.4 mg.2
What is the tingling skin side effect of Wegovy HD?
It is called dysesthesia: tingling, burning or sensitive skin. It affected 22 in 100 on 7.2 mg against 6 in 100 on 2.4 mg.2
How much does Wegovy HD cost?
Novo Nordisk’s self-pay price is $399 a month for one box of 4 pens, checked October 12, 2026.4
How we researched this
On October 12, 2026, we read the current US Wegovy label (revised June 2026), the FDA’s March 2026 press release, the STEP UP abstract, Novo Nordisk’s published self-pay prices and CMS’s Bridge prescriber sheet. Side-effect and result figures come from the US label.
STEP UP was paid for by Novo Nordisk, which makes Wegovy. The HD list price comes from Novo Nordisk’s own pricing page. We name no pharmacy, clinic or telehealth service, and leave out savings-card prices.
Before you move on
- Wegovy HD (7.2 mg) is for adults, after at least 4 weeks on 2.4 mg.
- It added about 3 points of weight loss over 2.4 mg in one 72-week trial.
- Nausea, vomiting and tingling skin (dysesthesia) were more common.
- The maker lists $399 a month self-pay; insurance coverage depends on your plan.
More from the US blog
The monthly US update
An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: FDA approvals and safety notices, label changes, Medicare and Medicaid coverage changes, and published price changes. How we write
Sources
- FDA. FDA approves fourth product under National Priority Voucher program, higher dose semaglutide. Press release, March 19, 2026. fda.gov
- Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information and Medication Guide, revised 06/2026. novo-pi.com
- Wharton S, Freitas P, Hjelmesæth J et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025;13(11):949–63. Funded by Novo Nordisk. DOI · PMID 40961952
- Novo Nordisk. Wegovy cost, coverage and savings resources (self-pay prices). NovoCare, opened October 12, 2026. novocare.com
- TrumpRx.gov (US government price-listing site). GLP‑1 listings with "original price", opened October 12, 2026. trumprx.gov
- Centers for Medicare & Medicaid Services (CMS). Medicare GLP‑1 Bridge: information for prescribers. CMS Product No. 12235, June 2026. cms.gov
- Poison Control (National Capital Poison Center). Opened October 12, 2026. poison.org
Last checked Oct 12, 2026 · Next review due Apr 12, 2027 · Report an error
How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical, legal or tax advice. Talk to a qualified doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. How we write